Evidences on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: A "breakthrough" in pharmacological treatment;Evidenze sul ruolo chiave dei recettori metabotropici del glutammato nell'eziopatogenesi della schizofrenia: Un "breakthrough" nel trattamento farmacologico

Rivista di Psichiatria

Volumn 47, Issue 2, 2012, Pages 149-169

  Pannese, Rossella ^a   Minichino, Amedeo ^a   Pignatelli, Marco ^a   Delle Chiaie, Roberto ^a   Biondi, Massimo ^a   Nicoletti, Ferdinando ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antipsychotics; Metabotropic glutamate receptors; NMDA receptors; Schizophrenia

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; EGLUMETAD; LY 41495; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG TARGETING; GENETIC SUSCEPTIBILITY; HUMAN; NERVE CELL DIFFERENTIATION; NERVE CELL EXCITABILITY; NEUROTRANSMISSION; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SYMPTOM; SYNAPTIC TRANSMISSION; TREATMENT INDICATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84861748185     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: 10.1708/1069.11719     Document Type: Review

References (81)

1. Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology? Science 2003; 299: 350-1. (Pubitemid 36120025)
2. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007; 12: 904-22. (Pubitemid 47482704)
3. Agid Y, Buzsaki G, Diamond DM, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007; 6: 189-201. (Pubitemid 46344623)
4. Norman RM, Malla AK, McLean T, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000; 102: 303-9.
5. Katschnig H. Schizophrenia and quality of life. Acta Psychiatr Scand Suppl 2000; 102: 33-7. (Pubitemid 32115744)
6. Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5-25. (Pubitemid 44693240)
7. Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl 1995; 388: 24-30.
8. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007; 164: 428-36. (Pubitemid 46513156)
9. Lieberman JA, Stroup TS, McEvoy JP, et al Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23. (Pubitemid 41345943)
10. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006; 31: 2033-46.
11. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30. (Pubitemid 26074706)
12. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018-28. (Pubitemid 34586949)
13. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000; 57: 249-58. (Pubitemid 30140434)
14. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176-84. (Pubitemid 32116511)
15. Marder SR, Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004; 72: 5-9. (Pubitemid 39452900)
16. Labhardt F. Largactil therapy in schizophrenia and other psychotic conditions. Schweiz Arch Neurol Psychiatr 1954; 73: 309-38.
17. Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5-25. (Pubitemid 44693240)
18. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment- resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
19. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91. (Pubitemid 36070868)
20. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018-28. (Pubitemid 34586949)
21. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77: 524-9.
22. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotictreatment. Am J Psychiatry 2006; 163: 600-10. (Pubitemid 44464569)
23. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68. (Pubitemid 29023554)
24. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23. (Pubitemid 41345943)
25. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-45. (Pubitemid 34275252)
26. Kozikowski AP, Roth B, Tropsha A. Why academic drug discovery makes sense. Science 2006; 313: 1235-6. (Pubitemid 44330930)
27. Roth BL. Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? Dialogues Clin Neurosci 2006; 8: 303-9. (Pubitemid 44682747)
28. Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology? Science 2003; 299: 350-1. (Pubitemid 36120025)
29. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extendedrelease tablets: a 6-week placebocontrolled trial. Schizophr Res 2007; 90: 147-61. (Pubitemid 46178537)
30. O'Connor KA, Roth BL. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005; 4: 1005-14.
31. Roth BL, Con PJ. IOM White Paper, 2006.
32. Sladeczek F, Pin JP, Récasens M, Bockaert J, Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 1985; 317: 717-19. (Pubitemid 16223634)
33. Hirono C, Ito I, Yamagishi S, Sugiyama H. Characterization of glutamate receptors induced in Xenopus oocytes after injection of rat brain mRNA. Neurosci Res 1988; 6: 106-14. (Pubitemid 19005228)
34. Minoshima T, Nakanishi S. Structural organization of the mouse metabotropic glutamate receptor subtype 3 gene and its regulation by growth factors in cultured cortical astrocytes. J Biochem 1999; 126: 889-96.
35. Nicoletti F, Battaglia G, Bruno V. Metabotropic glutamate receptors: molecular biology, pharmacology and cell biology.
36. Kunishima N, Shimada Y, Tsugji Y, et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000; 407; 971-7.
37. Bond A, Monn JA, Lodge D. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740. Neuroreport 1997; 8: 1463-6. (Pubitemid 27242555)
38. Monn JA, Valli MJ, Massey SM, et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999; 42: 1027-40. (Pubitemid 29153432)
39. Schoepp DD. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001; 299: 12-20. (Pubitemid 32905113)
40. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 2000; 292: 76-87. (Pubitemid 30026356)
41. Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Bristow LJ. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 2003; 28: 1622-32. (Pubitemid 41070863)
42. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 2001; 40: 847-55. (Pubitemid 32510798)
43. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000; 75:889-907. (Pubitemid 30660476)
44. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 1999; 29: 83-120. (Pubitemid 29016081)
45. Lam AG, Monn JA, Schoepp DD, Lodge D, McCulloch J. Group II selective metabotropic glutamate receptor agonists and local cerebral glucose use in the rat. J Cereb Blood Flow Metab 1999; 19: 1083-91. (Pubitemid 30167758)
46. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40: 881-4. (Pubitemid 37522046)
47. Adler CM, Malhotra AK, Elman I, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156: 1646-9. (Pubitemid 29460002)
48. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007; 32: 1888-902. (Pubitemid 47258508)
49. Collier DA, Li T. The genetics of schizophrenia: glutamate not dopamine? Eur J Pharmacol 2003; 480: 177-84. (Pubitemid 37410370)
50. Stefansson H, Steinthorsdottir V, Thorgeirsson TE, Gulcher JR, Stefansson K. Neuregulin 1 and schizophrenia. Ann Med 2004; 36: 62-71. (Pubitemid 38230700)
51. Andreasen NC, O'Leary DS, Flaum M, et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neurolepticnaïve patients. Lancet 1997; 349: 1730-4. (Pubitemid 27252672)
52. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004; 174: 39-44. (Pubitemid 38925089)
53. Crawford J, Curtis D. The excitation and depression of mammalian cortical neurons by amino acids. Br J Pharmacol 1964; 23: 323-9.
54. Hollmann M, Heimann S. Cloned glutamate receptors. Ann Rev Neurosci 1994; 17: 31-108. (Pubitemid 24117025)
55. Schoepp DD, Conn PJ. Metabotropic glutamate receptors. Pharmacol Biochem Behav 2002; 74: 255-6.
56. Huntley GW, Vickers JC, Morrison JH. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci 1994; 17: 536-43.
57. Nicoletti F, Wroblewski JT, Novelli A, Alho H, Guidotti A, Costa E. The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. J Neurosci 1986; 6: 1905-11. (Pubitemid 16064954)
58. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997; 37: 205-37. (Pubitemid 27238875)
59. Tamaru Y, Nomura S, Mizuno N, Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 2001; 106: 481-503. (Pubitemid 32925240)
60. Vardi N, Duvoisin R, Wu G, Sterling P. Localization of mGluR6 to dendrites of ON bipolar cells in primate retina. J Comp Neurol 2000; 423: 402-12. (Pubitemid 30451674)
61. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 361: 417-9. (Pubitemid 36164980)
62. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 2003; 160: 1100-9. (Pubitemid 41070969)
63. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825- 44.
64. Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord 2002; 1: 183-9.
65. Marino MJ, Conn JP. Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. Curr Drug Targets CNS Neurol Disord 2002; 1: 239-50.
66. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 2001; 21: 5925-34. (Pubitemid 32737725)
67. Attucci S, Albani-Torregrossa S, Moroni F, Pellegrini-Giampietro DE. Metabotropic glutamate receptors stimulate phospholipase D via different pathways in the adult and neonate rat hippocampus. Neurochem Res 2001; 26: 1151-5. (Pubitemid 33029467)
68. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002; 43: 1199-209. (Pubitemid 36084431)
69. Homayoun H, Jackson ME, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 2005; 93: 1989-2001. (Pubitemid 40404399)
70. Knoflach F, Mutel V, Jolidon S, et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A 2001; 98: 13402-7. (Pubitemid 33051375)
71. Marino MJ, Awad-Granko H, Ciombor KJ, Conn PJ. Haloperidol- induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata. Neuropharmacology 2002; 43: 147-59. (Pubitemid 35247603)
72. Battaglia G, Monn JA, Schoepp DD. In vivo inhibition of veratridine- evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 1997; 229: 161-4. (Pubitemid 27316071)
73. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-52. (Pubitemid 28406826)
74. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-7. (Pubitemid 27155025)
75. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001; 11: 569-77. (Pubitemid 33100377)
76. Johnson MP, Baez M, Jagdmann GE Jr, et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine. J Med Chem 2003; 46: 3189-92. (Pubitemid 36842403)
77. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003; 6: 189-97. (Pubitemid 37210425)
78. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003; 169: 215-33. (Pubitemid 37264943)
79. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42: 165-79. (Pubitemid 34160524)
80. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron 2006; 52: 179-96. (Pubitemid 44466363)
81. González-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci 2009; 32: 225-32.